<h2 class="mt-4 text-lg font-medium text-color-lightgreytext" data-astro-cid-fjd3bvuv>
Summary from the AllSides News Team
</h2> <div class="mt-2 text-md editor-content" data-astro-cid-fjd3bvuv><p>Pharmaceutical drugmaker Merck and its partner Ridgeback Biotherapeutics announced Monday that it has asked the Food and Drug Administration (FDA) for emergency approval of its&nbsp;COVID-19 pill. The company says the pill, called molnupiravir, reduced the risk of hospitalization or death in patients with mild to moderate COVID-19 by about 50% in a late-stage clinical trial.&nbsp;Researchers&nbsp;at Emory University in Atlanta created the pill; using the pill&nbsp;involves taking several twice a day for five days.&nbsp;The Biden administration <a href="/story/us-spend-32b-developing-antiviral-covid-19-pills">committed $3.2 billion to the development of an antiviral</a> in June.<br />
	<br />
	The news was covered prominently across the spectrum, especially by left- and center-rated outlets. Some reports from right-rated sources highlighted advocates who say the treatment's projected price — roughly $700 — is roughly 40 times the production cost.</p>
</div> <h2 class="mb-2 leading-6 text-lg text-gray-500 font-medium mt-4 p-0">
Featured Coverage of this Story
</h2> <div class="flex gap-5 my-2 mb-8 md:flex-row flex-col"> <div class="flex-1 center"><div class="mb-2 font-bold border-solid global-bias-label text-color-center border-b-[3px] text-s border-color-center">From the Center</div><a id="News-Item--what-we-know-and-don-t-know-about-merck-s-new-covid-19-pill" href="https://www.statnews.com/2021/10/04/what-we-know-and-dont-know-about-mercks-new-covid-19-pill/" target="_blank" rel="noopener"><div class="m-0 font-bold leading-tight text-md hover:underline text-base">What we know — and don’t know — about Merck’s new Covid-19 pill</div></a><div class="flex gap-2 items-center pt-2 hover:underline"><div class="overflow-hidden whitespace-nowrap"><p class="text-xs">STAT</p></div><img src="https://img.allsides.com/sites/default/files/bias-center.png" alt="AllSides Media Bias Rating: Center" title="AllSides Media Bias Rating: Center" width="72" height="12" class="news-source-bias-image shrink-0" style="width: 72px !important; height: 12px !important; max-width: 72px !important;"><div class="flex-1 text-right ml-2 text-xs text-gray-500 underline whitespace-nowrap">
See rating details
</div></div><div class="mt-4"><div class="relative w-full"><img src="https://img.allsides.com/sites/default/files/AP_080522074170-1600x900.jpg" alt="What we know — and don’t know — about Merck’s new Covid-19 pill" class="w-full h-auto object-cover"><div class="absolute bottom-0 left-0 right-0 h-12 bg-gradient-to-b from-color-transparent via-color-black/70 to-color-black px-1 pb-0 text-color-white flex items-end"><p class="text-xs pb-0.5">Mel Evans/AP</p></div></div></div><div class="mt-4"><div class="block text-xs leading-none mb-1 text-color-lightgreytext uppercase align-middle">News</div><div class="[&>p]:my-2 text-sm editor-content"><p>The&nbsp;announcement&nbsp;that a pill from Merck and partner Ridgeback Biotherapeutics kept Covid patients out of the hospital made headlines and moved stocks late last week. But as is so often true when data are released by press release, there are still many questions left unanswered.</p><p>Doctors are excited about the medicine, molnupiravir, because a regimen of pills, even one that involves taking several pills twice a day for five days, should be far easier to deliver to patients than current antiviral Covid-19 treatments, which must be given intravenously. But it’s still...</div><a id="Open-On--stat" class="text-xs inline-block border-b border-color-transparent no-underline font-bold whitespace-nowrap" href="https://www.statnews.com/2021/10/04/what-we-know-and-dont-know-about-mercks-new-covid-19-pill/" target="_blank" rel="noopener">
Open on STAT<i class="fa-regular fa-arrow-up-right-from-square ml-2"></i></a></div></div><script type="e8cc8d78a3b1fca395c5fe3f-module" src="/_astro/story-related-news.astro_astro_type_script_index_0_lang.DjPUAy8u.js"></script><div class="flex-1 right"><div class="mb-2 font-bold border-solid global-bias-label text-color-right border-b-[3px] text-s border-color-right">From the Right</div><a id="News-Item--merck-asks-fda-for-emergency-approval-of-its-antiviral-covid-19-pill" href="https://nypost.com/2021/10/11/merck-asks-fda-for-emergency-approval-of-its-antiviral-covid-19-pill/" target="_blank" rel="noopener"><div class="m-0 font-bold leading-tight text-md hover:underline text-base">Merck asks FDA for emergency approval of its antiviral COVID-19 pill</div></a><div class="flex gap-2 items-center pt-2 hover:underline"><div class="overflow-hidden whitespace-nowrap"><p class="text-xs">New York Post (News)</p></div><img src="https://img.allsides.com/sites/default/files/bias-leaning-right.png" alt="AllSides Media Bias Rating: Lean Right" title="AllSides Media Bias Rating: Lean Right" width="72" height="12" class="news-source-bias-image shrink-0" style="width: 72px !important; height: 12px !important; max-width: 72px !important;"><div class="flex-1 text-right ml-2 text-xs text-gray-500 underline whitespace-nowrap">
See rating details
</div></div><div class="mt-4"><div class="relative w-full"><img src="https://img.allsides.com/sites/default/files/merck-64.jpg" alt="Merck asks FDA for emergency approval of its antiviral COVID-19 pill" class="w-full h-auto object-cover"><div class="absolute bottom-0 left-0 right-0 h-12 bg-gradient-to-b from-color-transparent via-color-black/70 to-color-black px-1 pb-0 text-color-white flex items-end"><p class="text-xs pb-0.5">AP</p></div></div></div><div class="mt-4"><div class="block text-xs leading-none mb-1 text-color-lightgreytext uppercase align-middle">News</div><div class="[&>p]:my-2 text-sm editor-content"><p>Pharmaceutical giant Merck and its partner Ridgeback Biotherapeutics announced Monday that it has asked the Food and Drug Administration for emergency approval of its&nbsp;COVID-19 pill&nbsp;after the experimental drug&nbsp;showed “compelling results” in clinical trials.</p><p>The pill, called molnupiravir, cut the risk of hospitalization or death in patients with mild to moderate COVID-19 by about 50 percent in a late-stage trial, according to data from a phase three clinical trial shared earlier this month.</p><p>“The extraordinary impact of this pandemic demands that we move with unprecedented urgency, and that is what our...</div><a id="Open-On--new-york-post-news-" class="text-xs inline-block border-b border-color-transparent no-underline font-bold whitespace-nowrap" href="https://nypost.com/2021/10/11/merck-asks-fda-for-emergency-approval-of-its-antiviral-covid-19-pill/" target="_blank" rel="noopener">
Open on New York Post (News)<i class="fa-regular fa-arrow-up-right-from-square ml-2"></i></a></div></div><div class="flex-1 left"><div class="mb-2 font-bold border-solid global-bias-label text-color-left border-b-[3px] text-s border-color-left">From the Left</div><a id="News-Item--drugmakers-seek-fda-emergency-authorization-for-molnupiravir-antiviral-pill-to-treat-covid-19" href="https://www.usatoday.com/story/news/health/2021/10/11/covid-vaccinations-molnupiravir-antiviral-pill-cases/6083682001/" target="_blank" rel="noopener"><div class="m-0 font-bold leading-tight text-md hover:underline text-base">Drugmakers seek FDA emergency authorization for molnupiravir, antiviral pill to treat COVID-19</div></a><div class="flex gap-2 items-center pt-2 hover:underline"><div class="overflow-hidden whitespace-nowrap"><p class="text-xs">USA TODAY</p></div><img src="https://img.allsides.com/sites/default/files/bias-leaning-left.png" alt="AllSides Media Bias Rating: Lean Left" title="AllSides Media Bias Rating: Lean Left" width="72" height="12" class="news-source-bias-image shrink-0" style="width: 72px !important; height: 12px !important; max-width: 72px !important;"><div class="flex-1 text-right ml-2 text-xs text-gray-500 underline whitespace-nowrap">
See rating details
</div></div><div class="mt-4"><div class="relative w-full"><img src="https://img.allsides.com/sites/default/files/8fbba0e4-74ad-4c09-abf8-e3162ae32599-DELTA_08.jpg" alt="Drugmakers seek FDA emergency authorization for molnupiravir, antiviral pill to treat COVID-19" class="w-full h-auto object-cover"><div class="absolute bottom-0 left-0 right-0 h-12 bg-gradient-to-b from-color-transparent via-color-black/70 to-color-black px-1 pb-0 text-color-white flex items-end"><p class="text-xs pb-0.5">USA TODAY</p></div></div></div><div class="mt-4"><div class="block text-xs leading-none mb-1 text-color-lightgreytext uppercase align-middle">News</div><div class="[&>p]:my-2 text-sm editor-content"><p>Pharmaceutical companies Merck &amp; Co. and&nbsp;Ridgeback Biotherapeutics announced Monday&nbsp;the submission of emergency use authorization to the&nbsp;Food and Drug Administration&nbsp;for molnupiravir, an&nbsp;antiviral drug that&nbsp;offers the promise that COVID-19 could soon be treated by a pill.</p><p>Molnupiravir, an orally ingested antiviral pill, is used to treat&nbsp;mild to moderate adult cases of COVID-19 that are at risk of&nbsp;worsening to severe COVID-19 or hospitalization, according to the companies.&nbsp;It was&nbsp;created by researchers&nbsp;at Emory University in Atlanta and&nbsp;is given as four&nbsp;pills taken twice a day for five days.</p><p>An interim analysis from a clinical trial found&nbsp;the...</div><a id="Open-On--usa-today" class="text-xs inline-block border-b border-color-transparent no-underline font-bold whitespace-nowrap" href="https://www.usatoday.com/story/news/health/2021/10/11/covid-vaccinations-molnupiravir-antiviral-pill-cases/6083682001/" target="_blank" rel="noopener">
Open on USA TODAY<i class="fa-regular fa-arrow-up-right-from-square ml-2"></i></a><div class="flex-1 whitespace-nowrap text-gray-500 text-xs leading-4 flex mt-2"><div class="hover:cursor-help" data-tippy-content="<p><span style=&#34;white-space: nowrap;&#34;>Some content from this outlet may be</span><br><span style=&#34;white-space: nowrap;&#34;>limited or behind a paywall.</span></p>"><i class="fa-regular fa-sack-dollar mr-1"></i><span class="whitespace-nowrap">Possible Paywall</span></div></div></div></div> </div> <p class="mt-2 mb-5 text-right"> <a id="More-headline-roundups" class="group relative pr-5 hover:no-underline border-b border-opacity-0 hover:border-opacity-100 border-color-text inline-block w-fit cursor-pointer text-sm no-underline" href="/headline-roundups">